Elective percutaneous coronary intervention leads to significant changes in serum resistin, leptin, and adiponectin levels regardless of periprocedural myocardial injury: An observational study

Anatolian Journal of Cardiology

Volumn 16, Issue 12, 2016, Pages 940-946

  Buturak, Ali ^a   Değirmencioğlu, Aleks ^a   Bayrak, Fatih ^a   Kırış, Tuncay ^b   Karakurt, Hüseyin ^c   Demir, Ali Rıza ^c   Sürgit, Özgür ^c   Ertürk, Mehmet ^c  

^a ACIBADEM UNIVERSITY   (Turkey)

^b IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^c Istanbul Mehmet Akif Ersoy Cardiovascular Surgery Education and Research Hospital   (Turkey)

Author keywords

Adiponectin; Coronary; Leptin; Resistin

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; CLOPIDOGREL; HEPARIN; LEPTIN; RESISTIN; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY OBSTRUCTION; CROSS-SECTIONAL STUDY; EXERCISE TEST; FEMALE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PARTICIPANT OBSERVATION; PERCUTANEOUS CORONARY INTERVENTION; SCINTIGRAPHY; STENOSIS; AGED; BLOOD; HEART INFARCTION; METABOLISM;

ADIPONECTIN; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RESISTIN;

EID: 85006414812     PISSN: 21492263     EISSN: 21492271     Source Type: Journal    
DOI: 10.14744/AnatolJCardiol.2016.6876     Document Type: Article

References (44)

1. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, et al. Troponin elevations after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111: 1027-32.
2. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Euro Heart J 2011; 32: 23-31.
3. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102: 369-78.
4. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovas Interv 2008; 71: 318-24.
5. Alcock RF, Roy P, Adorini K, Lau GT, Kritharides L, Lowe HC, et al. Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation. Int J Cardiol 2010; 140: 66-72.
6. Zeng RX, Li XL, Zhang MZ, Guo YL, Zhu CG, Guo LH, et al. Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes. Atherosclerosis 2014; 237: 536-43.
7. Osugi N, Suzuki S, Ishii H, Yasuda Y, Shibata Y, Tatami Y, et al. Impact of albuminuria on the incidence of periprocedural myocardial injury in patients undergoing elective coronary stent implantation. Am J Cardiol 2014; 114: 42-6.
8. Madani M, Alizadeh K, Ghazaee SP, Zavarehee A, Abdi S, Shakerian F, et al. Elective percutaneous coronary intervention: the relationship between preprocedural blood glucose levels and periprocedural myocardial injury. Tex Heart Inst J 2013; 40: 410-7.
9. Buturak A, Değirmencioğlu A, Ertürk M, Karakurt H, Demir AR, Sürgit O, et al. Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention. Coron Artery Dis 2015; 26: 333-40.
10. Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013; 227: 216-21.
11. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocyto-kines in relation to cardiovascular disease. Metabolism 2013; 62: 1513-21.
12. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009; 53: 167-75.
13. Kitta Y, Takano H, Nakamura T, Kodama Y, Umetani K, Fujioka D, et al. Low adiponectin levels predict late in-stent restenosis after bare metal stenting in native coronary arteries. Int J Cardiol 2008; 131: 78-82.
14. Sako H, Miura S, Saku K. Significance of changes in plasma adiponectin concentration after the implantation of stents in patients with stable angina. J Cardiol 2008; 52: 17-23.
15. On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71: 868-73.
16. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007; 193: 121-8.
17. Shioji K, Moriwaki S, Takeuchi Y, Uegaito T, Mutsuo S, Matsuda M. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 2007; 71: 675-80.
18. Kreçki R, Krzemińska-Pakuła M, Peruga JZ, Szcześniak P, Lipiec P, Wierzbowska-Drabik K, et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011; 17: 26-32.
19. Chan KC, Chou HH, Huang CN, Chou MC. Atorvastatin administration after percutaneous coronary intervention in patients with coro- nary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clin Cardiol 2008; 31: 253-8.
20. Chu S, Ding W, Li K, Pang Y, Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008; 72: 1249-53.
21. Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Ho-kamaki J, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003; 89: 667.
22. Krone RJ, Shaw RE, Klein LW, Block PC, Anderson HV, Weintraub WS, et al. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current stent era of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol 2003; 92: 389-94.
23. rd, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation 1988; 78: 489-502.
24. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56: 254-61.
25. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-67.
26. Laurikka A, Vuolteenaho K, Toikkanen V, Rinne T, Leppanen T, Tark-ka M, et al. Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur J Cardiothorac Surg 2014; 46: 729-36.
27. Lee SE, Kim HS. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012; 48: 27-35.
28. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-40.
29. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011; 18: 108-14.
30. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005; 182: 241-8.
31. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295: H1514-21.
32. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954-60.
33. Jun JY, Ma Z, Pyla R, Segar L. Leptin treatment inhibits the progression of atherosclerosis by attenuating hypercholesterolemia in type 1 diabetic Ins2(+/Akita):apoE(-/-) mice. Atherosclerosis 2012; 225: 341-7.
34. Azar RR, Sarkis A, Salameh E, Gannagé-Yared MH, Amm-Azar M, Badaoui G, et al. Percutaneous coronary intervention increases leptin and decreases adiponectin levels. Clin Endocrinol (Oxf) 2006; 65: 712-6.
35. Finck BN, Johnson RW. Tumor necrosis factor (TNF)-alpha induces leptin production through the p55 TNF receptor. Am J Physiol Regul Integr Comp Physiol 2000; 278: R537-43.
36. Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, Alvord WG, et al. Interleukin 1 alpha increases serum leptin concentrations in humans. J Clin Endocrinol Metab 1997; 82: 3084-6.
37. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141-50.
38. Van Harmelen V, Reynisdottir S, Eriksson P, Thörne A, Hoffstedt J, Lönnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913-7.
39. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179-88.
40. Pischon T, Girman CJ, Hotamışlıgil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 29: 1730-7.
41. Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, Froguel P, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 243-54.
42. Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008; 375: 390-4.
43. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531-8.
44. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.